Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Clobetasol [1] Group 1: Company Information - Clobetasol is a phosphodiesterase 4 (PDE-4) inhibitor, indicated for topical treatment of mild to moderate atopic dermatitis in patients aged 3 months and older [1] - The company has 22 competitors in China with A registration status for Clobetasol raw materials [1] Group 2: Market Data - According to IMS data, the global sales figures for Clobetasol formulations are projected to be $224 million in 2022, $206 million in 2023, and $196 million in 2024 [1] - The consumption of Clobetasol raw materials is expected to be 706.68 kg in 2022, 963.57 kg in 2023, and 1118.43 kg in 2024 [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received approval for the marketing application of Clobetasol, a PDE-4 inhibitor, for treating mild to moderate atopic dermatitis in patients aged 3 months and older [1] Group 1: Company Developments - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the approval notice from the National Medical Products Administration for the marketing application of Clobetasol [1] - Clobetasol ointment is specifically indicated for local external treatment of atopic dermatitis [1] Group 2: Market Insights - There are currently 22 companies in China with A registration status for Clobetasol raw materials [1] - According to IMS data, the global sales figures for Clobetasol formulations are projected to be $224 million in 2022, $206 million in 2023, and $196 million in 2024 [1] - The consumption of Clobetasol raw materials is expected to be 706.68 kg in 2022, 963.57 kg in 2023, and 1118.43 kg in 2024 [1]